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symptoms did not provide additive predictive information for future shocks among ICD 
patients. More data is needed to explore further the elevation in risk among Class Ill-IV 
CHF patients. 
1064-Z implication of MADIT-II on Unselected Patients 
Following an Acute Myocardial Infarction 
Steen 2. Abildstrom, Christian Tarp-Pedersen, Lars Kober, National Institute of Public 
Health, Copenhagen, Denmark, Rigshospitalet, Copenhagen, Denmark 
Results: Qf the 5963 register patients alive at discharge 1009 patients (17%) fulfilled the 
MADIT-II criteria. Over a mean follow-up of 2.0 years 160 patients experienced SCD and 
227 non-sudden cardiac death. BBB was present in only 16% of the patients. BBB was 
associated with an increased risk of SCD, hazard ratio 1.50, P<O.O5. 
Conclusion: The frequency of sudden death in unselected Ml patients eligible for Madit II 
is high and we further confirm the increased potential of benefit in patients with bundle 
Background: In the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II) the 
prevalence of increased QRS interval (x0.12 set) was 50%. 
branch block. Bundle branch block is much more rare in unselected patients than in 
Increased QRS interval was associated with a trend towards an increased relative risk 
reduction of ICD treatment. We have therefore studied the prevalence of bundle branch 
patients enroled into Madit Il. 
block (BBB) in consecutive patients with myocardial infarction (Ml) eligible for MADIT-II 
and the risk of sudden cardiac death in patients eligible for MADIT-II. 
Methods: Consecutive Ml patients screened for TRACE in 1990.1992 were entered into 
a registry. MADIT-II selection criteria were applied (ejection fraction <=30%, NYHA func- 
tional class I to Ill). Sudden cardiac death (SCD) was defined as cardiovascular death 
within one hour of symptoms. The hazrad ratio was estimated by Cox regression analy- 
sis. 
1064-3 B-Blocker Reduces the Incidence of Appropriate 
Defibrillator Therapy in Patients With Congestive Heart 
Failure Secondary to Idiopathic Dilated 
Cardiomyopathy 
w Rlchard G. Trohman, Janet Haw, David G. Benditt, University of Minnesota, 
Minneapolis, MN, Rush-Presbyterian-St Luke’s Medical Center, Chicago, IL 
Background: pBlockers (BB) have been shown to reduce the total mortality and sudden 
cardiac death rates in patients with congestive heart failure (CHF). However, the effects 
of BB on the incidence of defibrillator (ICD) therapy in patients with CHF secondary to 
idiopathic dilated cardiomyopathy (IDCM) remain unknown. 
Methods and Results: Eighty-two patients (aged 51516 years) with IDCM who were 
treated with ICDs were enrolled in this study. Their left ventricular ejection fraction 
(LVEF) was 25*9%. These patients were regularly followed for a period of up lo 60 
months (mean 24 months). These patients received frequent appropriate (39%) and 
inappropriate (35%) ICD therapy. The first appropriate ICD therapy occurred at 7.6 
months (median). There was no significant difference between patients on (n=35) and ofl 
BB III age (50*17 vs 52*15 years, p>O.O5). LVEF (27+10% vs 24+6%, p>O.O5), or inci- 
dence of documented spontaneous or inducible sustained ventricular tachycardia I fibril- 
lation before implantation (39% vs 37%, p>O.O5). Fewer patients on BB were treated with 
amiodarone (14% vs 34%. p = 0.07). The incidence of appropriate ICD therapy was sig- 
nificantly lower in patients on BB than those off BB (26% vs 49%, log rank ~~0.05; Fig- 
ure). BB therapy was associated with a 47% reduction in appropriate ICD therapy in 
these patients. 
Conclusion : BB therapy may substantially reduce the incidence of appropriate ICD ther- 
apy in patients with CHF secondary to IDCM. 
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1064-4 Prevalence of Patients With Myocardial Infarction and 
Reduced Left Ventricular Ejection Fraction: Impact of 
MADIT-II Study in the General Population 
Param P. Sharma, Hector Osorio, Robert Greenlee, John Hayes, Peter N. Smith, Kelley 
P. Anderson, Humberto J. Vidaillet, Marshfield Clinic, Marshfield, WI 
Background: The second Multicenter Automatic Defibrillator Implant&ion trial (MADIT II) 
showed that defibrillators reduce all-cause mortality in patients with myocardial infarction 
(Ml) and low left ventricular ejection fraction (LVEF530). Precise estimates of the preva- 
lence of patients who meet MADIT II criteria could assist the assessment of the clinical 
and financial impact of the trial results. 
Methods: We used the resources of the Marshfield Epidemiological Study Area (MESA), 
a well defined geographic region in which Marshfield Clinic and St. Joseph’s hospital pro- 
vide nearlv all health care amona its 60.000 residents. Codes 410-410.92 from the gth 
edition of International Classification of Diseases were used to screen among current 
adult I> 21 vears) MESA residents that have survived a Ml between Janualv 1979 and ,_ _ 
February 2002. The entire medical record of each potential case was then reviewed to 
confirm MADIT II eligibility criteria: documented Ml and LVEF ( 30 %. Population preva- 
lence was calculated by age and gender using established MESA population denomina- 
tors. 
Results: Qf 1221 adults identified in the screening as having survived a MI, 1126 (92%) 
were confirmed by review of medical records. In those remaining, 112 (10%) pattents 
were shown to have an LVEF 5 30%. The 112 patients include 77 (69%) men and 71 
(63%) that are age 75 or older. Among adult MESA residents. the overall population 
prevalence of surviving an Ml and having an LVEF -< 30 % is 2.6 per 1,000 individuals 
(95% confidence interval 2.1-3.1). The prevalence per 1,000 was 3.6 among men and 
Conclusions: In MESA, nearly 10% of all patients with hlstory of a Ml meet MADIT II crite- 
1.6 among women. Prevalence rates ranged from cl per 1,000 among those ~55 years 
ria for defibrillator implantation. If our findings were applicable to the entire US popula- 
tion, we estimate there are 460,000 individuals in the United States that may benefit from 
old lo 21.7 per 1,000 in persons ~65 years. 
this technology. Further research is needed to determine whether the benefits experi- 
enced by the MADIT II study patients are generalizable to all individuals in the general 
population who meet the study criteria. 
1064-5 Are the Results of the Multicenter Automatic 
Defibrillator Implantation Trial-II Applicable to Patients 
Seen at a Tertiary Referral Center? 
Sana M. Al-Khatib. Yun Li, Kevin Anstrom. Eric Peterson, James Jollis, Christopher 
O’Connor, Kerry L. Lee, Linda Shaw. Robelt M. Califf. Duke University Medical Center, 
Durham, NC 
Background: Some physicians have questioned the applicabtllty of the results of the 
recently published Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II) to 
their patients. The purpose of this study is to determine the generalizability of the MADIT- 
II results. 
Methods: We used the Duke Cardiovascular Disease Database that has systematically 
collected the baseline characteristics and long-term follow-up of all patients who undergo 
a cardiac catheterization at our institution. We explored the baseltne characteristics of 
patients who met the MADIT-II inclusion criteria and examined their su~wal without an 
implantable cardioverter defibrillator (ICD). We estimated their life expectancy by assum- 
ing a Weibull distribution. The impact of ICD’s on life expectancy was determined by the 
relative risk reduction observed in MADIT-II assuming that the survival benefit from an 
ICD is constant over time. 
Results: Of patients undergoing cardiac catheterization between 1966 and 2001, 1392 
(2.7%) met the MADIT-II inclusion criteria. Our patients were similar to the MADIT-II 
patients in age (64 years, 25th and 75th percentiles of 55 and 71 years), ejectlon fraction 
(25%, 25th and 75th percentiles of 20% and 26%), history of hypertension, and history of 
diabetes. Our patients were less often male, less often smokers, and less often had left 
bundle branch block. Our patients were less likely to have symptomatic congestive heart 
failure and to have had revascularizatlon procedures. After 3 years of follow-up, the 
Kaplan-Meier survival estimates for the Duke cohort and the conventional arm of the 
MADIT-II population were very similar (66% vs. 69%). Applying the observed benefit 
from an ICD in MADIT-II to our population showed that their extrapolated survival esti- 
mate was slightly lower than the observed survival estimate for the MADIT-II ICD arm 
(75% vs. 76%). Our patients’ mean life expectancy was 7.5 years without an ICD and 
11.2 years with an ICD. 
Conclusions: Our patients’ baseline characteristics and survival pattern were similar to 
those of patients enrolled in MADIT-II. As such, the results of MADIT-II seem to be appli- 
cable to patients seen at a tertiary referral center. 
1064-6 Antiarrhythmic Agents May Decrease Long-Term 
Survival in Patients With Implantable Defibrillators 
Hankrishna S. Tandri, Lawrence C. Griffith, Tama Tang, Khurram Nasir, Chandrasekhar 
Vasam Reddy. Gordon Tomaselk. Henly Halperin, Charles Leng, Ronald D. Berger, 
Hugh Calkins, Donahue J. Kevin, The Johns Hopkins University, Baltimore, MD 
Antiarrhythmic agents are increasingly used for arrhythmia control and to reduce the inci- 
dence of shocks in pattents receiving Implantable defibrillators (ICD). The effect of these 
drugs on long-term survival of ICD patients is unknown. We constructed a database of 
1037 consecutive ICD Implants performed at our institution from February 1960 to Sep- 
tember 1999. Baseline variables collected included; demographics implant indication, 
NYHA functional class, cardiac diagnosis. co morbidity, discharge medication, echocar- 
dlography and angiography results. Details of discharge antiarrhythmic drug was wall- 
able in 796 patients (76%), 434 (57%) received antiarrhythmic on discharge (157 on 
class I and 257 on class Ill) and 392 (43%) were discharged on no drug therapy. 46% of 
